There are several ways to deal with emerging infectious disease risks. I think the way of the future for most blood operators will be the implementation of pathogen inactivation, as I mentioned before. This is a way of treating blood products to kill infectious agents.
As I mentioned, there are technologies, one already approved by Health Canada and one under review, that will allow pathogen inactivation for two blood components, which are platelets and plasma, and a technology for the treatment of red blood cells that is still under development.
I think that rather than looking at implementing a test every time there is a new disease that comes along, it makes a lot of sense to move towards this kind of technology.